Status:
UNKNOWN
The Effectiveness and Safety of 4% Sodium Citrate as a Lock Solution in Central Venous Hemodialysis Catheter
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Central Venous Catheter Thrombosis
Renal Dialysis
Eligibility:
All Genders
20+ years
Phase:
PHASE2
PHASE3
Brief Summary
Studies that used a dilute citrate formulation (4%) demonstrated efficacy as an anticoagulant with minimal to no risk of bleeding in HD sessions. This study will compare effectiveness and safety utili...
Detailed Description
Vascular access is necessary for hemodialysis(HD) procedure. In normal situation, vascular access for HD is created in peripheral vessels. However, vascular catheter may be considered in patients with...
Eligibility Criteria
Inclusion
- Age \>=20 years
- End-stage renal disease patients who received regular HD weekly via central venous catheter for at least 3 months in outpatient clinic in Kaohsiung Chang Gung Memorial Hospital, Taiwan
Exclusion
- bleeding tendency
- on radiotherapy or chemotherapy for malignancy
- pregnancy
- drug allergy history to citrate
- undefined reasons for refuted participation.
Key Trial Info
Start Date :
July 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05188339
Start Date
July 20 2022
End Date
December 31 2022
Last Update
July 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang Gung Memorial Hospital
Kaohsiung City, Taiwan